Allogene Therapeutics (ALLO) Asset Writedowns and Impairment (2023 - 2025)

Allogene Therapeutics has disclosed Asset Writedowns and Impairment across 3 years of filings, most recently posting $2.4 million for Q2 2025.

• Asset Writedowns and Impairment for Q2 2025 came in at $2.4 million, down 52.36% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.4 million (down 90.62% YoY), and the FY2025 annual result was $2.4 million, down 84.83% from the prior year.
• Asset Writedowns and Impairment came in at $2.4 million for Q2 2025 at Allogene Therapeutics, up from -$17000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $10.7 million in Q3 2024 to a low of -$17000.0 in Q4 2024.
• The 3-year median for Asset Writedowns and Impairment is $5.0 million (2024), against an average of $5.5 million.
• Across the five-year window, Asset Writedowns and Impairment tumbled 100.18% in 2024 and slumped 52.36% in 2025, its largest moves.
• Allogene Therapeutics' Asset Writedowns and Impairment stood at $9.5 million in 2023, then sank by 100.18% to -$17000.0 in 2024, then surged by 14111.76% to $2.4 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $2.4 million (Q2 2025), -$17000.0 (Q4 2024), and $10.7 million (Q3 2024), per Business Quant data.